Artificial Intelligence

Revealed: the pharma companies leading the way in artificial intelligence

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

Pfizer, Novartis, AstraZeneca, Johnson & Johnson, among others, are best positioned to benefit from investments in AI.

Pfizer and Novartis are among the companies best positioned to take advantage of future artificial intelligence disruption in the pharmaceuticals industry, our analysis shows.

The assessment comes from GlobalData’s Thematic Research ecosystem, which ranks companies on a scale of one to five based on their likelihood to tackle challenges like artificial intelligence and emerge as long-term winners of the pharmaceuticals sector.

According to our analysis, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Takeda, GSK, Bayer and Astellas Pharma are the companies best positioned to benefit from investments in artificial intelligence, all of them recording scores of five out of five in GlobalData’s Drug development Thematic Scorecard.

The table below shows how GlobalData analysts scored the biggest companies in the pharmaceuticals industry on their artificial intelligence performance, as well as the number of new artificial intelligence jobs, deals and patents from the companies since August 2021.

The final column in the table represents the overall score given to that company when it comes to their current artificial intelligence position relative to their peers. A score of five indicates that a company is a dominant player in this space, while companies that score less than three are vulnerable to being left behind. These can be read fairly straightforwardly.

The other data points in the table are more nuanced, showcasing recent artificial intelligence investment across a range of areas over the past year. These metrics, where available, give an indication of whether artificial intelligence is at the top of executives’ minds now, but high numbers in these fields are just as likely to represent desperate attempts to catch-up as they are genuine strength in artificial intelligence.

For example, a high number of deals could either indicate that a company is dominating the market, or that it is using mergers and acquisitions to fill in gaps in its offering.

This article is based on GlobalData research figures as of 19 August 2022. For more up-to-date figures, check the GlobalData website.

Go to top

02/24/2024 14:01:08

Jobs

North America is seeing a hiring jump in pharmaceutical industry big data roles

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

North America was followed by Europe, which saw a 0.5 year-on-year percentage point change in big data roles.

North America extended its dominance for big data hiring among pharmaceutical industry companies in the three months ending June.

The number of roles in North America made up 61.1% of total big data jobs - up from 60.3% in the same quarter last year.

That was followed by Europe, which saw a 0.5 year-on-year percentage point change in big data roles.

The figures are compiled by GlobalData, who track the number of new job postings from key companies in various sectors over time. Using textual analysis, these job advertisements are then classified thematically.

GlobalData's thematic approach to sector activity seeks to group key company information by topic to see which companies are best placed to weather the disruptions coming to their industries.

These key themes, which include big data, are chosen to cover "any issue that keeps a CEO awake at night".

By tracking them across job advertisements it allows us to see which companies are leading the way on specific issues and which are dragging their heels - and importantly where the market is expanding and contracting.

Which countries are seeing the most growth for big data job ads in the pharmaceutical industry?

The fastest growing country was India, which saw 5.3% of all big data job adverts in the three months ending June 2021, increasing to 7.5% in the three months ending June this year.

That was followed by the United States (up 0.899999999999999 percentage points), Germany (0.4), and France (0.4).

The top country for big data roles in the pharmaceutical industry is the United States which saw 58.8% of all roles advertised in the three months ending June.

Which cities and locations are the biggest hubs for big data workers in the pharmaceutical industry?

Some 4.1% of all pharmaceutical industry big data roles were advertised in Cambridge (United States) in the three months ending June.

That was followed by Bengaluru (India) with 2.9%, Boston (United States) with 2.8%, and Shanghai (China) with 1.6%.

Go to top

02/24/2024 12:22:40

Cloud Computing

Filings buzz in pharmaceuticals: 16% decrease in cloud computing mentions in Q2 2022

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

We've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.

Mentions of cloud computing within the filings of companies in the pharmaceutical industry fell 16% between the first and second quarters of 2022.

In total, the frequency of sentences related to cloud computing between July 2021 and June 2022 was 158% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Cloud computing is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether cloud computing is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned cloud computing at least once in filings during the past twelve months - this was 32% compared to 16% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to cloud computing.

Of the 10 biggest employers in the pharmaceutical industry, IQVIA was the company which referred to cloud computing the most between July 2021 and June 2022. GlobalData identified nine cloud-related sentences in the United States-based company's filings - 0.18% of all sentences. Sanofi mentioned cloud computing the second most - the issue was referred to in 0.09% of sentences in the company's filings. Other top employers with high cloud mentions included Pfizer, GSK and Roche.

This analysis provides an approximate indication of which companies are focusing on cloud computing and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning cloud computing more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into cloud computing have been successes or failures.

GlobalData also categorises cloud computing mentions by a series of subthemes. Of these subthemes, the most commonly referred to topic in the second quarter of 2022 was 'software as a service', which made up 87% of all cloud subtheme mentions by pharmaceutical companies.

Go to top

02/24/2024 13:37:37